Allstate Corp Purchases 16,592 Shares of Zoetis Inc. $ZTS

Allstate Corp boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 106.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,227 shares of the company’s stock after acquiring an additional 16,592 shares during the period. Allstate Corp’s holdings in Zoetis were worth $4,055,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fisher Asset Management LLC boosted its holdings in shares of Zoetis by 25.2% in the 4th quarter. Fisher Asset Management LLC now owns 2,975 shares of the company’s stock worth $374,000 after acquiring an additional 599 shares in the last quarter. Clearstead Trust LLC lifted its holdings in Zoetis by 541.7% during the 4th quarter. Clearstead Trust LLC now owns 3,497 shares of the company’s stock worth $440,000 after buying an additional 2,952 shares in the last quarter. Legal & General Group Plc lifted its holdings in Zoetis by 4.1% during the 4th quarter. Legal & General Group Plc now owns 3,554,498 shares of the company’s stock worth $447,227,000 after buying an additional 138,654 shares in the last quarter. Morningstar Investment Management LLC acquired a new position in Zoetis during the 4th quarter worth $6,264,000. Finally, Glenview Trust Co lifted its holdings in Zoetis by 13.6% during the 4th quarter. Glenview Trust Co now owns 5,849 shares of the company’s stock worth $736,000 after buying an additional 702 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Price Performance

ZTS opened at $79.48 on Thursday. The stock has a market cap of $33.32 billion, a P/E ratio of 13.18, a P/E/G ratio of 1.31 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $172.23. The company has a fifty day simple moving average of $105.95 and a 200 day simple moving average of $117.60.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts expect that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. Zoetis’s dividend payout ratio is presently 35.16%.

Wall Street Analyst Weigh In

ZTS has been the topic of several research reports. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, February 13th. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Six analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.